Can a ketone drink increase ATP in the brains of patients with Parkinson's disease?

Supplementation with a ketone ester drink to increase cerebral ATP in the brains of patients with Parkinson's disease as measured by magnetic resonance spectroscopy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN10531043

Enrollment

Registered

2018-12-07

Start date

2019-02-01

Completion date

Unknown

Last updated

2021-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson’s disease Nervous System Diseases Parkinson disease

Interventions

12 patients with Parkinson’s disease will undergo 31-phosphorus magnetic resonance spectroscopy (31-P MRS) imaging in order to determine their baseline cerebral ATP levels. They will also have a set o

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of Parkinson's disease 2. Hoehn and Yahr stages 1-2 3. Fluent in English 4. Capable of giving informed consent 5. Aged 40-80

Exclusion criteria

Exclusion criteria: 1. Communication impairments 2. Contraindications for undergoing magnetic resonance imaging (metal implants, claustrophobia) 3. Any disorder that the Principal Investigator deems may bias the study results or put the participant at risk

Design outcomes

Primary

Measure	Time frame
Cerebral ATP levels measured by 31-P MRS before and one hour after ingestion of the ketone supplement	—

Secondary

Measure	Time frame
Glucose, insulin, free fatty acid, and beta-hydroxybutyrate levels measured by standard laboratory blood assays before and one hour after ingestion of the ketone supplement	—

Countries

United Kingdom

Contacts

Public ContactNicholas Norwitz

nicholas.norwitz@dpag.ox.ac.uk+44 (0)7444 054375

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026